← All indications
Hyperlipoproteinemia Type II
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
Subtype terms (1)
More specific conditions that are subtypes of Hyperlipoproteinemia Type II in the MeSH hierarchy.
- Homozygous Familial Hypercholesterolemia
34 drugs (14 approved, 20 experimental)
Drugs by status
Approved for this indication (16)
Phase 3 trials (9)
Phase 2 trials (8)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (20)
- Karo Bio AB
- Daiichi Sankyo
- Takeda
- The Medicines Company
- Pfizer
- Novartis
- Amryt Research Limited
- Innovent Biologics (Suzhou) Co. Ltd.
- Ionis Pharmaceuticals, Inc.
- Kastle Therapeutics, LLC
- Pronova BioPharma
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- Mayo Clinic
- Food and Drug Administration
- University of Amsterdam
- University of the Witwatersrand
- Nordland Hospital
- LIB Therapeutics LLC
- The FH Foundation
Organization Involved with Phase 2 Indications (19)
- Abionyx
- Gemphire Therapeutics, Inc.
- Hengrui Therapeutics, Inc.
- Japan Tobacco Inc.
- Medical Research Laboratories International
- CymaBay Therapeutics, Inc.
- PharmaNet
- University of London
- Capital Medical University
- University of Naples Frederico II
- Akros
- University of Montreal
- Madrigal Pharmaceuticals
- Dr. Reddy's Laboratories
- Doris Duke Charitable Foundation
- Akcea Therapeutics
- Chinese Academy of Medical Sciences
- Akeso Pharmaceuticals, Inc.
- AD Pharmaceuticals Co., Ltd. (Guangzhou)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (8)